An annual report lists Taiwan-related trade issues being followed in Washington. Early each year, the Office of the U.S. Trade Representative (USTR) releases a country-by-country Report on Foreign Trade Barriers. The nine-page Taiwan section for 2020 provides a concise statement of the main areas of U.S.-government concern regarding elements of the bilateral trade relationship. Taiwan’s…

AmCham’s Pharmaceutical Committee has suggestions. Year after year, a key concern of the major pharmaceutical companies operating in Taiwan is the ease with which new drugs and new indications (meaning new applications for existing treatments) can enter the market. Given Taiwan’s single-payer universal healthcare system, much depends on whether the National Health Insurance Administration (NHIA)…

Taiwan’s establishment of a well-formulated Patent Linkage system for pharmaceuticals is a landmark development not only for the drug industry but for this country’s intellectual property rights protection in general. In addition, it boosts Taiwan’s status in the global trading community and improves its prospects for eventually concluding bilateral or multilateral free trade agreements with…

It’s imperative to devote more resources to infectious-disease control, leading to the development of new antibiotics. In 2015, the U.S. White House launched a national action plan against antimicrobial resistance (AMR), also commonly known as antibiotic resistance. In 2017, the World Health Organization (WHO) announced the 12 types of highly resistant bacteria that pose the…

If you’ve taken any medicine lately in the Asia-Pacific region, it’s highly likely that Zuellig Pharma delivered it to your healthcare provider or pharmacy. Distributing pharmaceuticals is a complex business involving cold-chain management and other massive logistical challenges that most of us take for granted. The company’s mission is to make healthcare more accessible to…

The Novartis motto – “Reimagining Medicine” – goes to the heart of the company’s deep commitment to developing innovative drugs to help fill the unmet needs of patients worldwide. The Swiss-based pharmaceutical multinational consistently ranks among the top companies investing in R&D, ensuring a constant pipeline of new and groundbreaking treatments. In 2017 the investment…